Sangeetha Somayajula1, Belma Dogdas1, Xiaohai Wang2, Mansuo Hayashi2, Shubing Wang3, Sofia Apreleva3, Richard Baumgartner3, Denise Welsh4, Xiangjung Meng4, Diane Posavec4, Amy Vanko4, Jacquelynn Cook4, Donald S. Williams4, Alexandre Coimbra4
1Informatics IT, Merck & Co., Inc, West Point, PA, United States; 2Neurology, Merck & Co. Inc, West Point, PA; 3Biometrics, Merck & Co. Inc; 4Imaging, Merck & Co. Inc
We study the use of volumetric MRI (vMRI) for characterization of longitudinal changes, response to therapy, and relationship between vMRI measurements and post-mortem biochemical measurements, in the rTg4510 transgenic mouse model for Alzheimer's disease. We use a low resolution (0.2 mm isotropic), high throughput imaging sequence and automated atlas based segmentation to measure volumes of regions of interest (ROIs) over time and across groups (positive and negative controls, and test compound). The data acquisition and analysis is sensitive to positive control therapy and also highlight specific brain ROIs that respond to therapy and show high correlation with biochemical phenotype.